I thought the analysis on this board regarding Inmed & Nemus has been pretty accurate. I have to agree with Vinpat in regards to the fact that their biosynthesis is wildly inflated and may not be that beneficial as opposed to what other companies are doing.
Their entire claim behind their technology/software is speed, which is that their process allows them to identify cannabinoids best suited for certain diseases without doing heavy amount of trials and research. Theoretically, this would mean that they would be able to identify a variety of targets faster than any other company, or so they claim.
However, right now they have only two targets in their pipeline, meanwhile they've been at it with this system of biosynthesis for years.
See below for Seeking Alpha article from March 2015. They have essentially missed all expected timelines and are not much further along then they were over 2 years ago. Their pipeline has actually shrinked, and they haven't advanced on those targets.
If their science was that superb, you'd think they would have been further along or wouldve been able to secure more funding by now. The 5 million raise will keep them afloat for now but they are clearly very far behind in moving towards trials.
"Schneider signed a non-disclosure and got to see and hear everything." After the fact, but they didn't invest because they knew a deal was imminent. Besides, if a deal were to be signed before phase 1 which is at least 8 months away, they wouldn't have raised so much, so soon.
It wasn't the valuation, but that he thinks Schneider was expecting a 50x+ return. That's not how it works at all.
News 
Market Data 
Discover 
